Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$19.35 -2.8%	$18.11	$16.10 ▼ $42.47	$2.50B	0.67	2.37 million shs	1.31 million shs
ARWR Arrowhead Pharmaceuticals	$17.63 -5.3%	$16.05	$9.57 ▼ $30.41	$2.57B	0.93	1.57 million shs	1.46 million shs
EOLS Evolus	$9.27 -2.5%	$9.66	$8.67 ▼ $17.82	$613.17M	0.97	768,132 shs	1.31 million shs
NAMS NewAmsterdam Pharma	$21.02 -5.2%	$19.18	$14.06 ▼ $27.29	$2.49B	-0.03	740,015 shs	445,146 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-2.81%	+8.16%	+2.76%	+6.55%	-51.63%
ARWR Arrowhead Pharmaceuticals	-5.27%	+0.51%	+12.01%	+55.33%	-38.91%
EOLS Evolus	-2.52%	+0.11%	-6.65%	-8.31%	-23.20%
NAMS NewAmsterdam Pharma	-5.19%	+5.00%	+4.01%	+31.13%	+7.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.2873 of 5 stars	4.3	0.0	4.4	2.3	2.5	0.6
ARWR Arrowhead Pharmaceuticals	3.6014 of 5 stars	3.4	2.0	3.4	2.1	1.7	0.0
EOLS Evolus	3.9358 of 5 stars	3.5	0.0	3.5	2.6	3.3	0.6
NAMS NewAmsterdam Pharma	2.7744 of 5 stars	3.5	2.0	0.0	1.6	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$39.79	105.63% Upside
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	147.95% Upside
EOLS Evolus	3.00	Buy	$23.75	156.20% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	104.04% Upside

Current Analyst Ratings Breakdown

Latest EOLS, ARWR, APLS, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	3.11	N/A	N/A	$1.84 per share	10.52
ARWR Arrowhead Pharmaceuticals	$3.55M	685.83	N/A	N/A	$1.54 per share	11.45
EOLS Evolus	$275.46M	2.17	N/A	N/A	$0.09 per share	103.00
NAMS NewAmsterdam Pharma	$45.56M	51.80	N/A	N/A	$8.20 per share	2.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	21.89	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)

Latest EOLS, ARWR, APLS, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	N/A	N/A	N/A	$1.44 million	N/A
7/30/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
EOLS Evolus	22.00	2.34	2.16
NAMS NewAmsterdam Pharma	N/A	19.98	19.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
ARWR Arrowhead Pharmaceuticals	62.61%
EOLS Evolus	90.69%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.80%
ARWR Arrowhead Pharmaceuticals	4.30%
EOLS Evolus	6.10%
NAMS NewAmsterdam Pharma	20.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.14 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
EOLS Evolus	170	64.48 million	60.54 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable

EOLS, ARWR, APLS, and NAMS Headlines

Recent News About These Companies

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of "Buy" from Analysts

July 14 at 4:39 AM | americanbankingnews.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Buy" from Analysts

July 14 at 4:37 AM | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 5.7% - Still a Buy?

July 9, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded to Hold at Wall Street Zen

July 6, 2025 | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by Wall Street Zen

July 5, 2025 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Purchases 1,260 Shares

June 27, 2025 | insidertrades.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Purchases 1,260 Shares

June 26, 2025 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Buys 2,520 Shares

June 26, 2025 | marketbeat.com

First Week of February 2026 Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq

June 24, 2025 | nasdaq.com

NewAmsterdam Pharma Company N.V. (NAMS) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

NewAmsterdam Pharma (NASDAQ:NAMS) Downgraded by Wall Street Zen to "Sell"

June 21, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up - Time to Buy?

June 20, 2025 | marketbeat.com

James N. Topper Acquires 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

June 19, 2025 | insidertrades.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Rating of "Buy" by Analysts

June 19, 2025 | marketbeat.com

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug

June 18, 2025 | investing.com

James N. Topper Purchases 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

June 18, 2025 | marketbeat.com

Insider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 100,000 Shares of Stock

June 18, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Analysts at Citigroup

June 17, 2025 | marketbeat.com

5NAMS : What Analysts Are Saying About NewAmsterdam Pharma...

June 12, 2025 | benzinga.com

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities

June 12, 2025 | tipranks.com

Stifel Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation

June 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS, ARWR, APLS, and NAMS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$19.35 -0.56 (-2.81%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$19.27 -0.08 (-0.41%)

As of 07/15/2025 07:46 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$17.63 -0.98 (-5.27%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$17.98 +0.36 (+2.01%)

As of 07/15/2025 07:38 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Evolus NASDAQ:EOLS

$9.27 -0.24 (-2.52%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$9.24 -0.04 (-0.38%)

As of 07/15/2025 07:34 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

NewAmsterdam Pharma NASDAQ:NAMS

$21.02 -1.15 (-5.19%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$21.02 0.00 (0.00%)

As of 07/15/2025 04:29 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time